AbbVie Increases Quarterly Dividend by 11 Percent
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +8.8%
Join SI Premium – FREE
NORTH CHICAGO, Ill., Oct. 27, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 11 percent from $0.64 per share to $0.71 per share.
The cash dividend is payable February 15, 2018 to shareholders of record at the close of business on January 12, 2018.
Since the company's inception in 2013, AbbVie has increased its dividend by more than 77 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVieAbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

View original content with multimedia:http://www.prnewswire.com/news-releases/abbvie-increases-quarterly-dividend-by-11-percent-300544624.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
- TotalEnergies SE: Disclosure of Transactions in Own Shares
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, Dividend, Dividend AristocratsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share